Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Closed Research Teams
  • View item
  • Home
  • ICR Divisions
  • Closed Research Teams
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Quantifiable mRNA transcripts for tamoxifen-metabolising enzymes in human endometrium

Thumbnail
Date
2008-07-10
ICR Author
Phillips, David Hunter
Author
Singh, MN
Stringfellow, HF
Walsh, MJ
Ashton, KM
Paraskevaidis, E
Abdo, KR
Martin-Hirsch, PL
Phillips, DH
Martin, FL
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
Tamoxifen has been used in the management of receptor-positive breast cancer for >20 years. Usage confers an elevated risk of developing endometrial carcinoma. Its mechanism of carcinogenicity remains unresolved with controversy as to whether or not this is mediated through a genotoxic mechanism. Usage is not only associated with an elevated occurrence of endometrioid endometrial carcinoma, but also type 2 and mixed epithelial-stromal tumours (MESTs) that have a poorer prognosis. Following hysterectomy, endometrial tissues (n = 18) classified as benign (n = 6), non-tamoxifen-associated carcinoma (n = 6) and tamoxifen-associated carcinoma (n = 6) were obtained; quantitative gene expression was performed. Employing real-time RT-PCR, the relative gene expressions of phase I/II metabolic enzymes CYP1A2, CYP1B1 and CYP3A4, cathechol-O-methyltransferase (COMT) and SULT2A1 were ascertained. Measurable mRNA transcripts, especially for those genes associated with tamoxifen bioactivation, were quantifiable in all the tissues examined. Whether this is evidence that generation of genotoxic tamoxifen metabolites may occur in human endometrial tissue remains to be ascertained. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
URI
https://repository.icr.ac.uk/handle/internal/2439
DOI
https://doi.org/10.1016/j.tox.2008.04.009
Collections
  • Closed Research Teams
Research team
Human Biomonitoring & Carcinogen Activation
Language
eng
License start date
2008-07-10
Citation
TOXICOLOGY, 2008, 249 pp. 85 - 90
Publisher
ELSEVIER IRELAND LTD

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.